)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Zevra Therapeutics
Zevra Therapeutics (ZVRA) investor relations material
Zevra Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary3 Nov, 2026
Executive summary
Q3 2026 net revenue rose 45% YoY to $37.8 million, including $34.0 million from MIPLYFFA; net income was $19.2 million.
Priorities include expanding MIPLYFFA access, pursuing European access to arimoclomol, and advancing celiprolol for vascular Ehlers-Danlos syndrome.
Financial highlights
Q3 revenue was $37.8 million versus $26.1 million in Q3 2025; operating expenses were $24.1 million, including $4.9 million R&D and $19.1 million SG&A.
Q3 net income was $19.2 million, or $0.31 basic and $0.26 diluted EPS, versus a $0.5 million net loss and $0.01 loss per share in Q3 2025.
Nine-month revenue was $113.6 million versus $72.3 million; reported net income was $65.9 million versus $71.1 million in 2025.
Nine-month operating cash flow was $33.2 million versus cash used of $7.1 million in 2025; investing cash flow was $76.2 million and financing cash use was $49.7 million.
Outlook and guidance
FDA feedback supports a planned MIPLYFFA sNDA for patients under 24 months in Q1 2027; this age group is estimated at ~5% of the addressable market.
A CHMP opinion on arimoclomol re-examination is expected in Q4 2026; the re-examination outcome remains pending.
The celiprolol team is developing a statistical analysis plan incorporating retrospective real-world data, with further FDA discussion intended for H1 2027.
Available resources were considered sufficient for existing and planned capital needs for at least the next 12 months; near-term cash flow may be minimal or negative.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Zevra Therapeutics
- MIPLYFFA adoption, $75.9M H1 revenue and a late-stage pipeline underpin growth.ZVRA
Corporate presentation - Strong H1 2026 revenue and pipeline advances position the company for rare disease leadership.ZVRACorporate presentation
- Broader patient reach, data-driven growth, and global expansion drive rare disease strategy.ZVRAH.C. Wainwright 28th Annual Global Investment Conference
- Rapid U.S. growth, global expansion, and a strong pipeline drive rare disease innovation.ZVRAMorgan Stanley 24th Annual Global Healthcare Conference
- Strong commercial execution, expanding patient base, and pipeline drive rare disease growth.ZVRA12th Annual Cantor Fitzgerald Global Healthcare Conference
- Integrated commercial and clinical strategies are expanding rare disease market reach and pipeline.ZVRACanaccord Genuity's 46th Annual Growth Conference
- Strong H1 2026 revenue and cash position support growth in rare disease therapeutics.ZVRACorporate presentation
- Q2 2026 revenue surged 53% to $39.7M, with strong cash reserves and pipeline progress.ZVRAQ2 2026
- Miplyffa's U.S. launch and $150M PRV sale extend cash runway and support 2025 growth.ZVRAQ4 2024
Next Zevra Therapeutics earnings date
Q4 20269 Mar, 2027
Zevra Therapeutics
Next Zevra Therapeutics earnings date
Q4 20269 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Zevra Therapeutics Inc., previously known as KemPharm Inc., is a biopharmaceutical company specializing in the development of proprietary prodrugs for the treatment of serious medical conditions, with a focus on rare diseases. The company utilizes its Ligand Activated Therapy technology to create enhanced versions of FDA-approved drugs and new compounds for potential new disease indications. Zevra's product pipeline includes KP1077, designed for the treatment of idiopathic hypersomnia (IH) and narcolepsy, and KP879 for stimulant use disorder, both in Phase II clinical trials. Additionally, Zevra has FDA-approved products like AZSTARYS for attention deficit hyperactivity disorder and APADAZ, a combination treatment containing a prodrug of hydrocodone and acetaminophen. The company is headquartered in Celebration, Florida, and its shares are listed on the NASDAQ.